TrialThe lancet. Gastroenterology & hepatology2026

Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial.

Vipul Jairath et al.PubMed ↗Publisher ↗

No numbers read from the abstract.